
News|Articles|March 1, 2002
Arixtra (Fondaparinux sodium injection), Organon/Sanofi-Synthelabo
New biologic: Factor Xa inhibitor for reducing risk of blood clotsafter orthopedic surgeries
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
5


























